Brief: UCB Receives U.S. FDA Breakthrough Therapy Designation For CIMZIA In Pregnant Women With Antiphospholipid Syndrome
09/09/2026 06:08
BRIEF-UCB Receives U.S. FDA Breakthrough Therapy Designation For CIMZIA In Pregnant Women With Antiphospholipid Syndrome Sept 9 (Reuters) - Ucb SA UCB.BR:
RECEIVES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR CIMZIA[®] (CERTOLIZUMAB PEGOL) IN PREGNANT WOMEN WITH ANTIPHOSPHOLIPID SYNDROME (APS)
Source text: nPLX2F8J2R
Further company coverage: UCB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on UCB SA
See all newsUCB tops STOXX after guidance upgrade on better drug sales
UCB upgrades 2026 guidance on strong US Bimzelx sales (updated)
UCB upgrades 2026 guidance on strong US Bimzelx sales
Brief: UCB Eyes Low- To Mid-Forties FY Adjusted EBITDA Growth
Brief: UCB Annouces FDA Approval For Zilbrysq Autoinjector Self-Administration For Adults Living With Generalized Myasthenia Gravis